Table 1 Clinical characteristics of MCL patients
Patient ID | Diagnosis | Treatment | Immunophenotype |
|---|---|---|---|
1 (DA) | MCL | Treatment naive | CD5+CD19+ (86.1%+) |
2 (U-21-0319) | MCL | Treatment naive | CD5+CD19+ (85.5%+) |
3 (U-21-2484) | MCL | R/R status post chemotherapy including ASCT, targeted therapies including ibrutinib and venetoclax, and progressed after commercial CD19 CAR-Ts | CD5+CD19+ (95.2%+) |
4 (U-18-0530) | MCL | Treatment naive | CD5+CD19+ (85.4%+) |
5 (U-19-1409) | MCL | R/R status post chemotherapy and ibrutinib | CD5−CD19+ (73.7%+) |